Diabetic kidney disease: seven questions
- Author:
Dong Ho YANG
1
;
So Young LEE
Author Information
- Publication Type:Original Article
- Keywords: Diabetic nephropathies; Biomarkers; Diagnosis; Treatment
- MeSH: Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biopsy; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetic Nephropathies; Diagnosis; Humans; Kidney; Kidney Failure, Chronic; Mortality; Renal Replacement Therapy
- From:Journal of the Korean Medical Association 2020;63(1):6-13
- CountryRepublic of Korea
- Language:Korean
- Abstract: Diabetic kidney disease is a microvascular complication of diabetes mellitus and the leading cause of end-stage renal disease resulting in renal replacement therapy. Approximately 30% to 40% of diabetic patients have diabetic kidney disease, which contributes to a significant increase in morbidity and mortality. Microalbuminuria is considered the gold standard for diabetic kidney disease diagnosis; however, its predictive value is restricted. Although blood glucose control, blood pressure control, and angiotensin converting enzyme inhibitors have been the primary treatment strategies, there are no definitive treatment modalities capable of inhibiting the progression of kidney dysfunction in these patients. This study was undertaken to answer seven questions regarding the various aspects of diabetic kidney disease. Why does it develop? what kind of factors affect its development? How is it diagnosed? What are its possible biomarkers? When is a kidney biopsy necessary? What are the preventive and therapeutic options? And what are the novel treatments?
